App-Quantinova.ai

Takotsubo Cardiomyopathy Associated with Levothyroxine over-Replacement

Joana Guimaraes - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Levothyroxine

Dramatically Elevated Serum TSH Responsive to Treatment in a Patient with Hashimoto Thyroiditis, Renal Failure and Cardiomyopathy

Stanley Chen Cardenas - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Heart muscle disease

Levothyroxine

Thyroid Hormone Resistance Associated with Difficult to Control Atrial Arrhythmias

Imali Sirisena - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Heart muscle disease

Warfarin

Sarcopenia and Non-Ischemic Cardiomyopathy After Liver Transplantation

A. Mathew - American Transplant Congress (ATC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Dobutamine

Isolated heart transplantation for left heart failure in a CF patient

S. Barth - European Cystic Fibrosis Conference (ECFC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Mycophenolic acid

Angiotensin-(1-7) prevents fibrosis in doxorubicin-treated rats

Omeed A. Rahimi - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Doxorubicin

Role of autophagy as potential molecular mechanism in trastuzumab-induced cardiotoxicity

Nishant Mohan - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Trastuzumab

Determining the association between adverse clinical outcomes and inadequate chest pain control in acute coronary syndrome: a case-control pilot study

E. Osgood - American Pain Society (APS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Utilization of Aldosterone Receptor Antagonists at Discharge in Patients Hospitalized With Heart Failure and a Reduced Ejection Fraction

Chris Domenico - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Heart muscle disease

Methadone hydrochloride

Survival and Implantable Cardioverter-Debrillator Deactivation in End-Stage Congestive Heart Failure Patients

Lillian C. Man - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Dobutamine

No Increase in Mortality Seen with ?-blocker Treatment in Heart Failure Patients with Cocaine Use

Peter Nguyen - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Heart muscle disease

N/A

Elevated Transpulmonary Gradient is a Predictor of Survival in Patients with WHO Group II Pulmonary Hypertension Treated with Continuous-flow Left Ventricular Assist Devices (CF-LVAD)

Javier Amione-Guerra - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Race, Gender and Clinical Characteristics Do Not Predict Outcomes in End-Stage Heart Failure Patients Requiring Inotropes

Charles D. Nicolais - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Dobutamine

Medical Management of Patients with the HeartMate II Left Ventricular Assist Devices. A Single Center Experience

Adam F. Burdorf - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Inverse Changes in Quality of Life for Patients and Caregivers After Implantation of a Ventricular Assist Device

Julie T. Bidwell - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Prevalence of Heart Failure in Different Sickle Cell Variants by Age, Gender, and Systolic Dysfunction

Sadeer Alkindi - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

N/A

Peripartum Cardiomyopathy Network: Medication and Device Therapy Use in the First Year

Kismet Rasmusson - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

Spironolactone

A novel mutation for McLeod neuroacanthocytosis

Hiller, A - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Heart muscle disease

N/A

Correlation Between Coronary Sinus, Arterial and Venous BNP Levels in Subjects with Reduced Left Ventricular Systolic Function

Zubair Shah - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Cardiac Rotational Mechanics as a Predictor of Favorable Functional and Structural Response After Mechanical Unloading With Cardiac Assist Devices in Advanced Heart Failure Patients

Michael J. Bonios - Heart Failure Society of America (HFSA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Filters

3340 Abstracts